WCN26-6551 PCSK9 Inhibition Attenuates Renal Lipotoxicity by Activating AMPK in Diabetic Kidney Disease

20260 citationsJournal Articlegold Open Access

Authors

Keum-Jin Yang · The Catholic University of Korea Daejeon St. Mary's Hospital

Soonha Lee · The Catholic University of Korea Daejeon St. Mary's Hospital

Sungmi Kim · St. Mary's Hospital

Sojung Youn · The Catholic University of Korea Bucheon St. Mary's Hospital

Hwajin Park · St. Mary's Hospital

Yunkyung Hwang · St. Mary's Hospital

Suyeon Han

Abstract

Conclusion:Based on Round 1, panelists favored SGLT2is as a foundational therapy for adults with CKD and T2D, with GLP-1 RAs considered for obesity, metabolic risk, ASCVD, or in combination with SGLT2i for persistent kidney disease progression.These initial insights emphasize kidney protection as an early treatment goal.

Topics & Keywords

Metabolism, Diabetes, and Cancer Chronic Kidney Disease and Diabetes Diabetes Treatment and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Kidney International Reports

Volume 11, Issue 4, pp. 104634-104634

DOI: 10.1016/j.ekir.2026.104634

Field-Weighted Citation Impact: 0.00